ArdorComm Media Group

Vaccines

India Became ‘Pharmacy of the World’ During Covid-19: JP Nadda

ArdorComm news

Union Minister of Health and Family Welfare, JP Nadda, hailed India as the ‘Pharmacy of the World’ on Monday while emphasizing the country’s significant contributions to global healthcare during the Covid-19 pandemic. Nadda was speaking at the 19th International Conference of Drug Regulatory Authorities (ICDRA) in New Delhi, where leaders from over 120 countries gathered to discuss regulatory practices and collaborative solutions to enhance global healthcare standards. “This prestigious platform [19th ICDRA] reflects our shared commitment to enhancing global healthcare standards and safeguarding public health,” Nadda said. He highlighted India’s pivotal role in addressing global health challenges through innovation, resilience, and collaboration. India’s Covid-19 Response: Vaccine Production and Global Impact Nadda elaborated on India’s rapid response during the pandemic, particularly its ability to ramp up vaccine production to meet both domestic and international needs. “During the unprecedented Covid-19 pandemic, India emerged not only as a global leader in health resilience and innovation but also reaffirmed its role as the pharmacy of the world,” he said. India’s extensive vaccination campaign, which successfully inoculated over a billion people, was described as a major milestone. Nadda credited healthcare workers and government initiatives for ensuring affordable access to essential medicines, vaccines, and medical supplies for nations around the globe. He also underscored India’s assistance to over 150 countries during the pandemic, driven by the ethos of “Vasudhaiva Kutumbakam,” the ancient Indian philosophy that emphasizes “the world is one family.” Cross-Border Collaboration and Regulatory Advancements Nadda emphasized that cross-border collaboration is essential for addressing global healthcare challenges. “The theme of this conference resonates deeply with our core belief that collaboration across borders, sectors, and disciplines is essential for creating lasting health solutions,” he stated. He also outlined India’s efforts to modernize its regulatory framework, highlighting the establishment of eight operational drug testing laboratories, with two more in the pipeline. Furthermore, eight mini testing labs have been set up at various ports to expedite the testing of imported materials. Over 95 percent of regulatory processes in India have been digitized, and the country’s medical device industry is now under regulation. With India’s healthcare system playing a crucial role in ensuring affordable access to medical supplies and vaccines during the pandemic, Nadda emphasized the importance of continued innovation and global cooperation to build a healthier, more resilient world. Source: Business Standard

Healthcare Innovation Set to Double, Reaching $60 Billion Opportunity in India by FY28

A recent report by Bain & Company and HealthQuad reveals a promising outlook for healthcare innovation in India, projecting its value to double to $60 billion by FY28. This growth surge is part of India’s broader healthcare market, expected to reach $320 billion by the same time, driven by a compound annual growth rate (CAGR) of 12%. Healthcare innovation currently constitutes 15% ($30 billion) of India’s healthcare market, with approximately 55% of it export-oriented. Aarthi Rao from Bain & Company anticipates substantial expansion, emphasizing not only value engineering but also business innovation, particularly in biotech, vaccines, and med-tech sectors. The report identifies four key segments driving healthcare innovation: pharma services, health-tech, vaccines, and biotech, and med-tech. Health-tech, which includes consumer-facing solutions like telemedicine and enterprise-facing solutions like B2B e-commerce, witnessed a significant boost, doubling from $3 billion in FY20 to $7 billion in FY23. India’s success in the vaccines and biotech market has been remarkable, with revenues reaching $4 billion in FY23, driven by exports. The country has become a vaccine powerhouse, supplying around 60% of global vaccine demand. Additionally, biotech startups are leveraging new technologies to develop innovative products. Pharma services remain a dominant force, constituting around 50% of the healthcare innovation market. India’s pharma services market, valued at $16 billion in FY23, has seen significant growth driven by exports and the country’s emergence as a leading CDMO player globally. Charles-Antoine Jannsen from HealthQuad notes India’s evolution in the biologics space, emphasizing its newfound strengths in research, manufacturing, and export. The accelerated adoption of telemedicine and e-pharmacies during the pandemic has further propelled health-tech growth. Overall, India’s healthcare innovation landscape presents a compelling growth story, driven by technological advancements, favorable government initiatives, and an expanding global footprint.  

WHO Launches Biomanufacturing Workforce Training Initiative for Global Health Resilience

The World Health Organization (WHO) has unveiled the WHO Biomanufacturing Workforce Training Initiative in response to the COVID-19 pandemic’s impact on global supply chains, particularly affecting low- and middle-income countries’ access to essential medical products. This initiative aims to address the shortage of biomanufacturing capacity and qualified workforce in LMICs, which hinders the local production of biological products crucial for addressing global health challenges. Coordinated by the Local Production and Assistance (LPA) Unit of WHO, in collaboration with the WHO Academy and WHO Science Division, the initiative will provide accessible and tailored training programs aligned with international standards. Dr. Jicui Dong, Unit Head of the LPA Unit, will lead the initiative, focusing on three pillars: existing capacity-building activities within WHO, the Global Training Hub for Biomanufacturing (GTH-B), and regional training centers. WHO’s capacity-building programs have a track record of success in providing technical assistance to manufacturers and Member States. These programs include virtual and hands-on training sessions tailored to real-life scenarios, promoting sustainable and quality local production. The GTH-B, established in 2023 with the Republic of Korea, offers training programs on manufacturing best practices and vaccinology to LMICs, including hands-on training in manufacturing facilities. Regional training centers, as recommended by the 2nd World Local Production Forum, will further enhance geographical diversity and resource synchronization. Expressions of interest for regional training centers to join the global network under the Biomanufacturing Workforce Training Initiative will be invited soon. By enhancing bioproduction capabilities in LMICs, the WHO Biomanufacturing Workforce Training Initiative seeks to strengthen global health resilience and address disparities in access to essential medical products. This initiative underscores WHO’s commitment to promoting equitable solutions and building a skilled workforce to combat current and future health challenges.

G20 Health Ministers Unite for Resilient and Equitable Access to Affordable Medicines in Developing Nations

During the G20 Health Ministers meeting, a consensus emerged to establish stronger, more inclusive health systems that provide fair access to safe, quality, and affordable vaccines, therapeutics, diagnostics, and medical countermeasures, particularly in low and middle-income countries and small island developing states. The outcome document, consisting of 25 paragraphs, received unanimous approval from all G20 delegations, except for paragraph 22, which focused on the geopolitical situation in Ukraine. According to the released outcome document after the meeting in Gandhinagar on August 19, there was agreement on creating a research and development network for vaccines, therapeutics, and diagnostics. Additionally, plans were made to establish a platform for readily accessible open-source and interoperable digital solutions. Health ministers also expressed optimism about the ongoing negotiations within the intergovernmental negotiating body (INB) for a legally binding WHO convention or international instrument related to pandemic prevention and preparedness, with a target of achieving this by May 2024. They recognized the need to fortify health systems against the impacts of climate change and pledged to prioritize the development of climate-resilient health systems. This includes creating sustainable and low-carbon/low greenhouse gas (GHG) emission healthcare systems and supply chains that offer high-quality care and mobilizing resources for resilient, low-carbon health systems. The G20 member countries committed to addressing antimicrobial resistance (AMR) comprehensively through a One Health approach. This entails strengthening governance, coordination, research and development, infection prevention and control, and improving awareness of AMR. Responsible use of antimicrobials across humans, animals, and plant sectors, along with preserving existing therapeutics through antimicrobial stewardship, was also emphasized. Moreover, the G20 recognized the potential of evidence-based traditional and complementary medicine (T&CM) in public health delivery, provided that these practices are scientifically validated for safety and effectiveness. They also acknowledged the significance of digital health and the modernization of health data systems in improving healthcare accessibility and equity. The ministers recommended closer coordination among existing digital health initiatives to create a seamless digital health ecosystem, endorsing the WHO’s Global Initiative on Digital Health to implement the WHO’s Global Digital Health Strategy 2020-2025. This initiative, managed by the WHO, aims to reduce fragmentation, promote interoperable open-source digital solutions, and support countries in implementing high-quality digital health systems with a people-centric focus.